Tevogen signs letter of intent to evaluate CRO acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P, Dow edge higher on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization
February 27, 2026 2:20 PM ESTWARREN, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Tevogen (Tevogen Bio Holdings Inc. or Company) (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (LoI) to evaluate a potential transaction with a distinguished global Contract Research Organization (CRO). If consummated, the... More
